| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 05/06/1999 | EP0913472A2 Human LIG-1 Homolog (HLIG-1) |
| 05/06/1999 | EP0913471A2 Cdna clone HNEAA81 that encodes a human 7-transmembrane receptor |
| 05/06/1999 | EP0913155A2 Pharmaceutical formulation for treating liver disorders |
| 05/06/1999 | EP0912741A2 T-cell selective interleukin-4 agonists |
| 05/06/1999 | EP0912735A2 Secreted proteins and polynucleotides encoding them |
| 05/06/1999 | EP0912731A2 Secreted proteins |
| 05/06/1999 | EP0912602A1 Method of treating beta-amyloid peptide associated conditions using trh |
| 05/06/1999 | EP0912601A1 Suppression of immune response via inhibition of cathepsin s |
| 05/06/1999 | EP0912600A2 Peptidomimetic inhibitors of cathepsin d and plasmepsins i and ii |
| 05/06/1999 | EP0912569A1 Preparation of (7s,trans)-2-(2-pyrimidinyl)-7-(hydroxymethyl)octahydro-2h-pyrido 1,2-a]pyrazine |
| 05/06/1999 | EP0912558A1 Substituted indazole derivatives and their use as phosphodiesterase (pde) type iv and tumor necrosis factor (tnf) inhibitors |
| 05/06/1999 | EP0912554A1 Indoline derivatives useful as 5-ht-2c receptor antagonists |
| 05/06/1999 | EP0912545A1 Hydroxamic acid based collagenase inhibitors |
| 05/06/1999 | EP0912534A1 Muscarinic antagonists |
| 05/06/1999 | EP0912533A1 Alkylaminobenzothiazole and -benzoxazole derivatives |
| 05/06/1999 | EP0912518A1 Substituted pyridines as selective cyclooxygenase-2 inhibitors |
| 05/06/1999 | EP0912516A1 Anticonvulsant pyridinyl benzamide derivatives |
| 05/06/1999 | EP0912515A1 1,4-di-sustituted piperidines as muscarinic antagonists |
| 05/06/1999 | EP0912512A1 Sulphonamide derivatives and their use in the treatment of cns disorders |
| 05/06/1999 | EP0912505A1 Il-8 receptor antagonists |
| 05/06/1999 | EP0912496A1 Inhibition of matrix metalloproteases by acetylene containing compounds |
| 05/06/1999 | EP0912494A1 Coumpounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases |
| 05/06/1999 | EP0912184A1 Use of k-252a derivative for the treatment of peripheral or central nerve disorders, and cytokine overproduction |
| 05/06/1999 | EP0912183A1 Heterocyclic compounds |
| 05/06/1999 | EP0912174A1 Alteration of circadian rhythmicity with a tachykinin antagonist |
| 05/06/1999 | EP0912086A1 Regulation of alzheimer's disease related proteins and uses thereof |
| 05/06/1999 | EP0772604B1 Triazole compounds and their use as dopamine-d3-ligands |
| 05/06/1999 | EP0750607B1 2-(aminoalkoxy)phenylalkylamines with antiinflammatory activity |
| 05/06/1999 | EP0737187B1 Benzoxazine derivatives, methods for obtaining same and their use as drugs |
| 05/06/1999 | EP0688320B1 Tricyclic benzodiazepins, their use and preparation |
| 05/06/1999 | EP0623114B1 Phenyl imidazolidinone derivatives, process for their preparation and their use as 5ht3 receptor antagonists |
| 05/06/1999 | CA2308454A1 Antagonists of gonadotropin releasing hormone |
| 05/06/1999 | CA2308453A1 Method of reducing craving in mammals |
| 05/06/1999 | CA2307826A1 Enhancement of morphogen activity |
| 05/06/1999 | CA2307748A1 Aminomethyl-benzo[a]quinolizidine derivatives, preparation and therapeutic applications for neurodegenrative diseases |
| 05/06/1999 | CA2307320A1 148 human secreted proteins |
| 05/06/1999 | CA2307030A1 Substituted isoquinoline derivatives and their use as anticonvulsants |
| 05/06/1999 | CA2306878A1 Bis-quaternary ammonium derivatives as neuromuscular relaxants |
| 05/06/1999 | CA2306817A1 Treatment of schizophrenia with ampakines and neuroleptics |
| 05/06/1999 | CA2305258A1 3-substituted tetrahydropyridopyrimidinone derivatives, method for producing the same, and their use |
| 05/05/1999 | CN1216043A Substd. benzenesulfonamide derivs as prodrugs of COX-2 inhibitors |
| 05/05/1999 | CN1216036A Novel tetralone or benzopyranone derivs and process for producing same |
| 05/05/1999 | CN1215996A Indications for use as medicaments of multipotent parapox immunity inducers from attenuated, non-immunogenic pox viruses or parapox viruses |
| 05/05/1999 | CN1215992A Method for treating emesis and central nervous system disorders using optically pure (+) norcisapride |
| 05/05/1999 | CN1043230C Serotoninergic ergoline derivs. |
| 05/04/1999 | US5900436 Therapy for lipid metabolism disorders |
| 05/04/1999 | US5900420 Method for treating chronic fatigue syndrome and fibromyalgia with buprenorphine |
| 05/04/1999 | US5900409 Cerebration improver |
| 05/04/1999 | US5900257 Cosmetic/pharmaceutical compositions comprising lanthanide manganese, tin and/or yttrium salts as substance P antagonists |
| 05/04/1999 | US5900247 Mucoadhesive pharmaceutical composition for the controlled release of active principles |
| 05/04/1999 | CA2063689C Ibuprofen lysinate pharmaceutical formulation |
| 04/30/1999 | CA2248996A1 Novel ornithine carbamoyltransferase |
| 04/29/1999 | WO1999020764A1 Robo: a family of polypeptides and nucleic acids involved in nerve guidance |
| 04/29/1999 | WO1999020646A1 Estra-1,3,5(10)-triene-7alpha-thioethers |
| 04/29/1999 | WO1999020643A1 Using polyamide nucleic acid oligomers to engender a biological response |
| 04/29/1999 | WO1999020633A1 Benzoxazine derivatives, preparation and application in therapy |
| 04/29/1999 | WO1999020624A1 Bicyclic kinase inhibitors |
| 04/29/1999 | WO1999020622A1 3-oxo-2(h)-1,2,4-triazine derivatives as ligands of 5ht1a receptors |
| 04/29/1999 | WO1999020621A1 ARYLPIPERAZINES AS SEROTONIN REUPTAKE INHIBITORS AND 5-HT1Dα ANTAGONISTS |
| 04/29/1999 | WO1999020616A1 2-substituted 1,2-benzisothiazole derivatives and their use as serotonin antagonists (5-ht1a, 5-ht1b and 5-ht1d) |
| 04/29/1999 | WO1999020614A1 Bicyclic compounds, process for their preparation and pharmaceutical compositions containing them |
| 04/29/1999 | WO1999020613A1 Cyclohexane derivatives difunctionalised in 1,4 as ligands of 5t h1a receptors |
| 04/29/1999 | WO1999020599A1 Pharmaceutically active compounds and methods of use |
| 04/29/1999 | WO1999020291A2 Pharmaceutical grade ginkgo biloba |
| 04/29/1999 | WO1999020279A1 Potentiation of pharmaceuticals |
| 04/29/1999 | WO1999020278A1 Use of moxonidine for the treatment of depression |
| 04/29/1999 | WO1999020268A1 (3r,4r)-δ-tetrahydrocannabinol-11-oic acids useful as antiinflammatory agents and analgesics |
| 04/29/1999 | WO1999020262A1 Remedy for meniere disease |
| 04/29/1999 | WO1999020260A2 The use of inhibitors of the renin-angiotensin system for the treatment of hypoxia or impaired metabolic function |
| 04/29/1999 | WO1999020255A1 Oral morphine multiparticulate formulation |
| 04/29/1999 | WO1999006066A3 Catalytic monoclonal antibodies with protease activity for the selective lysis of the protein component of plaques and aggregates related to pathological conditions |
| 04/29/1999 | WO1999004775A9 Method of treating dopaminergic and gaba-nergic disorders |
| 04/29/1999 | WO1999003822A9 Bicyclic metabotropic glutamate receptor ligands |
| 04/29/1999 | DE19756864C1 Production of neuronal or glial progenitor cells |
| 04/29/1999 | DE19747063A1 New 3-substituted tetrahydropyridopyrimidinone derivatives |
| 04/29/1999 | DE19746612A1 New 2-substituted 1,2-benzisothiazole derivatives |
| 04/29/1999 | CA2558783A1 Oral morphine multiparticulate formulation |
| 04/29/1999 | CA2308773A1 Estra-1,3,5(10)-triene-7alpha-thioethers |
| 04/29/1999 | CA2307597A1 Pharmaceutically active compounds and methods of use |
| 04/29/1999 | CA2307308A1 Medicine for treatment of meniere's disease |
| 04/29/1999 | CA2307288A1 (3r,4r)-.delta.-tetrahydrocannabinol-11-oic acids useful as antiinflammatory agents and analgesics |
| 04/29/1999 | CA2307199A1 2-substituted 1,2-benzisothiazole derivatives and their use as serotonin antagonists (5-ht1a, 5-ht1b and 5-ht1d) |
| 04/29/1999 | CA2307194A1 Pharmaceutical grade ginkgo biloba |
| 04/29/1999 | CA2307114A1 Arylpiperazines as serotonin reuptake inhibitors and 5-ht1d.alpha. antagonists |
| 04/29/1999 | CA2306982A1 Use of moxonidine for the treatment of depression |
| 04/29/1999 | CA2306870A1 Bicyclic kinase inhibitors |
| 04/29/1999 | CA2306731A1 Using polyamide nucleic acid oligomers to engender a biological response |
| 04/29/1999 | CA2306233A1 Potentiation of pharmaceuticals |
| 04/28/1999 | EP0911633A1 A method of identifying agonists and antagonists for tumor necrosis related receptors TR1, TR3 and TR5 |
| 04/28/1999 | EP0911406A2 Histidine kinase from Staphylococcus aureus |
| 04/28/1999 | EP0911403A2 MurB gene from Streptococcus pneumoniae |
| 04/28/1999 | EP0911402A2 PyrR homolog from Staphylococcus aureus |
| 04/28/1999 | EP0911399A2 A kringle-related clone, HTHBZ47 |
| 04/28/1999 | EP0911398A2 Phosphorylation epitopes of Tau protein for the diagnosis and treatment of Alzheimer's disease |
| 04/28/1999 | EP0911390A2 Protein kinases as tools for the diagnosis and treatment of Alzheimer's disease |
| 04/28/1999 | EP0911331A2 Substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use |
| 04/28/1999 | EP0910579A1 Compounds with growth hormone releasing properties |
| 04/28/1999 | EP0910567A1 Tricyclic ibogaine analogs, their preparation and their use in treating substance abuse |
| 04/28/1999 | EP0910566A1 Heterocyclic compounds and their preparation and use |
| 04/28/1999 | EP0910565A1 Amide derivatives as selective neuropeptide y receptor antagonists |